Singapore markets open in 3 hours 41 minutes

Straits Times Index
3,330.01
-8.93(-0.27%)
S&P 500
5,354.03
+62.69(+1.18%)
Dow
38,807.33
+96.04(+0.25%)
Nasdaq
17,187.90
+330.86(+1.96%)
Bitcoin USD
71,123.69
+702.43(+1.00%)
CMC Crypto 200
1,517.11
+43.37(+2.94%)

Prothena Corporation plc (0PT.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR

Add to watchlist

20.40

0.00

(0.00%)

At close: 09:50PM CEST

Loading interactive chart…

Zacks
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
Business Wire
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
DUBLIN, May 28, 2024--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.
Simply Wall St.
News Flash: Analysts Just Made A Notable Upgrade To Their Prothena Corporation plc (NASDAQ:PRTA) Forecasts
Celebrations may be in order for Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, with the analysts delivering a...